Compare NPKI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | ABCL |
|---|---|---|
| Founded | 1932 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 2020 |
| Metric | NPKI | ABCL |
|---|---|---|
| Price | $13.53 | $3.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.17 | $7.75 |
| AVG Volume (30 Days) | 722.6K | ★ 2.9M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $14.60 | N/A |
| Revenue Next Year | $12.80 | $16.59 |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $4.76 | $1.89 |
| 52 Week High | $15.85 | $6.52 |
| Indicator | NPKI | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 46.24 |
| Support Level | $13.31 | $3.37 |
| Resistance Level | $14.00 | $3.84 |
| Average True Range (ATR) | 0.51 | 0.16 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 33.97 | 9.52 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.